ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,303.27
      0.12%
      US Tech 100
      18,066.00
      -0.07%
      Dow Jones
      40,003.59
      0.34%
      Brent Oil
      83.76
      0.00%
      Bitcoin
      66,938.93
      -0.21%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Dare Bioscience Inc (DARE)

      7. Dare Bioscience Inc (DARE) News

      DARE

      Dare Bioscience (DARE)

      Dare Bioscience Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:DARE
      DateTimeSourceHeadlineSymbolCompany
      3:00PMiHub NewswireFeaturedMusic Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements
      05/14/20244:01PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DAREDare Bioscience Inc
      05/14/20248:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:DAREDare Bioscience Inc
      05/14/20248:00AMGlobeNewswire Inc.Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company UpdateNASDAQ:DAREDare Bioscience Inc
      05/13/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:DAREDare Bioscience Inc
      05/10/20244:12PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:DAREDare Bioscience Inc
      05/07/20248:00AMGlobeNewswire Inc.Daré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024NASDAQ:DAREDare Bioscience Inc
      05/02/20248:00AMGlobeNewswire Inc.Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke NetworkNASDAQ:DAREDare Bioscience Inc
      04/30/20247:30AMGlobeNewswire Inc.Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key CatalystsNASDAQ:DAREDare Bioscience Inc
      04/23/20248:00AMGlobeNewswire Inc.Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1NASDAQ:DAREDare Bioscience Inc
      04/11/20248:00AMGlobeNewswire Inc.Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal ContraceptiveNASDAQ:DAREDare Bioscience Inc
      03/28/20248:00AMGlobeNewswire Inc.Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company UpdateNASDAQ:DAREDare Bioscience Inc
      03/28/20247:42AMIH Market NewsUS Stock Futures Stable in Pre-Market On Path for Consecutive Quarterly Gains, Oil Prices RiseNASDAQ:DAREDare Bioscience Inc
      03/21/20248:00AMGlobeNewswire Inc.Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024NASDAQ:DAREDare Bioscience Inc
      02/22/20248:00AMGlobeNewswire Inc.Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual MeetingNASDAQ:DAREDare Bioscience Inc
      01/31/20248:00AMGlobeNewswire Inc.Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024NASDAQ:DAREDare Bioscience Inc
      01/29/20244:18PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:DAREDare Bioscience Inc
      01/26/20245:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:DAREDare Bioscience Inc
      01/26/20244:30PMGlobeNewswire Inc.Daré Bioscience Announces Executive Team and Board of Directors ChangesNASDAQ:DAREDare Bioscience Inc
      01/19/20244:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:DAREDare Bioscience Inc
      01/17/20248:00AMGlobeNewswire Inc.Daré Bioscience Announces Grant to Support Biotherapeutic Product DevelopmentNASDAQ:DAREDare Bioscience Inc
      01/08/20248:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:DAREDare Bioscience Inc
      01/04/20248:00AMGlobeNewswire Inc.Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of DiseasesNASDAQ:DAREDare Bioscience Inc
      12/26/20234:05PMEdgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:DAREDare Bioscience Inc
      12/26/20238:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:DAREDare Bioscience Inc
      12/26/20238:00AMGlobeNewswire Inc.Daré Bioscience Secures $12 million in Royalty-backed Investment StructureNASDAQ:DAREDare Bioscience Inc
      12/20/20238:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:DAREDare Bioscience Inc
      12/20/20238:00AMGlobeNewswire Inc.Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical StudyNASDAQ:DAREDare Bioscience Inc
      12/13/20238:00AMGlobeNewswire Inc.Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical StudyNASDAQ:DAREDare Bioscience Inc
      12/07/20238:00AMGlobeNewswire Inc.Daré Bioscience Announces FDA Clearance of Investigational New Drug (IND) Application for DARE-VVA1, a Novel Intravaginal Formulation of Tamoxifen for Moderate to Severe Dyspareunia, a Symptom of Vulvar and Vaginal Atrophy Associated with MenopauseNASDAQ:DAREDare Bioscience Inc
       Showing the most relevant articles for your search:NASDAQ:DARE